1. HAE Prophylaxis

2. This program will include a discussion of investigational agents not approved by the FDA for use in the United States.

3. HAE Resulting From C1INH Deficiency

4. HAE Burden of Disease

5. HAE Burden of Disease (cont)

6. Impact of Therapies for HAE, Post-2009

7. Long-Term Prophylaxis for HAE

8. Long-Term Prophylaxis Androgens

9. Long-Term Prophylaxis IV-Infused C1INH

10. Long-Term Prophylaxis SC-Injected C1INH

11. Impact on QoL With SC-Injected C1INH

12. Impact on QoL With SC-Injected C1INH (cont)

13. Emerging Therapies for Prophylactic Use

14. Concluding Remarks

15. Abbreviations

16. Abbreviations (cont)